Dantsov A A, Kovaleva L M, Grigor'eva I F, Drozdova M V
Vestn Otorinolaringol. 1994 May-Jun(3):31-4.
Upon a clinical and audiological examination of 92 children with adhesive otitis media the patients were assigned to standard treatment or to treatment with a new proteolytic enzyme collalysin. The indications to these therapies were based on the degree of cicatrization, hearing loss and the disease duration. Conventional treatment yielded effect only in the disease duration less than 3 years, an insignificant hearing loss and nonsevere tympanic scars. Otoscopic, acoustic and tympanometric improvement after collalysin electrophoresis was observed in marked scars of the tympanic membrane, in a hearing loss by more than 30 dB, in shorter duration of the disease. 80% of the patients on collalysin functionally benefited from the treatment.
对92例粘连性中耳炎患儿进行临床和听力学检查后，将患者分为标准治疗组或使用新型蛋白水解酶胶原酶进行治疗。这些治疗的适应症基于瘢痕化程度、听力损失和病程。传统治疗仅在病程小于3年、听力损失不显著且鼓膜瘢痕不严重的情况下有效。在鼓膜明显瘢痕、听力损失超过30dB、病程较短的情况下，胶原酶电泳后观察到耳镜、声学和鼓室图改善。80%接受胶原酶治疗的患者在功能上从治疗中受益。
